Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
243.91
-7.16 (-2.85%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Ascendis Pharma Financials Overview
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 865.78 | 720.13 | 363.64 | 266.72 | 51.17 | 7.78 |
Revenue Growth | 134.82% | 98.03% | 36.34% | 421.20% | 557.93% | 11.87% |
Gross Profit Gross Profit Growth | 770.87 | 625.22 | 319.38 | 222.32 | 39.04 | 4.26 |
Operating Income Operating Income Growth | -7.25 | -136.27 | -278.76 | -455.54 | -561.81 | -451.79 |
Net Income Net Income Growth | 495.93 | -228.03 | -378.08 | -481.45 | -583.19 | -383.58 |
Earnings Per Share EPS Growth | 7.38 | -3.76 | -6.53 | -8.55 | -10.40 | -7.00 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
YORVIPATH YORVIPATH Growth | 629.62 | 477.41 | 28.73 | - | - | - |
SKYTROFA SKYTROFA Growth | 198.78 | 206.16 | 197 | 178.66 | 35.66 | 0.94 |
Services and Clinical Supply Services and Clinical Supply Growth | 19.59 | 18.01 | 15.57 | 21.98 | 12.97 | 4.47 |
Licenses Licenses Growth | 4.87 | 5.63 | 122.34 | 66.08 | 2.55 | 2.37 |
Milestones Milestones Growth | - | 12.92 | - | - | - | - |
Revenue (Total) Revenue (Total) Growth | 865.78 | 720.13 | 363.64 | 266.72 | 51.17 | 7.78 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 572.82 | 616.04 | 559.54 | 399.44 | 735.46 | 682.06 |
Total Debt Total Debt Growth | 896.66 | 871.79 | 856.62 | 644.27 | 508.38 | 104.96 |
Net Cash (Debt) Net Cash Growth | -323.84 | -255.75 | -297.07 | -244.83 | 227.08 | 577.1 |
Net Cash Growth | - | - | - | - | -60.65% | -7.93% |
Net Cash Per Share Net Cash Per Share Growth | -5.17 | -4.22 | -5.13 | -4.35 | 4.05 | 10.54 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 60.49 | 53.9 | -306.2 | -467.36 | -495.7 | -417.65 |
Capital Expenditures CapEx Growth | - | - | - | - | - | -23.7 |
Free Cash Flow Free Cash Flow Growth | 60.49 | 53.9 | -306.2 | -467.36 | -495.7 | -441.35 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 89.04% | 86.82% | 87.83% | 83.36% | 76.28% | 54.71% |
Operating Margin | -0.84% | -18.92% | -76.66% | -170.80% | -1097.85% | -5808.59% |
Pretax Margin | -19.32% | -29.53% | -102.64% | -177.77% | -1129.12% | -4936.28% |
Profit Margin | 57.28% | -31.67% | -103.97% | -180.51% | -1139.63% | -4931.56% |
FCF Margin | 6.99% | 7.48% | -84.20% | -175.23% | -968.65% | -5674.38% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
P/FCF Ratio | 309.77 | 208.99 | - | - | - | - |
PS Ratio | 16.11 | 15.64 | 21.77 | 24.16 | 124.46 | 833.09 |